PTC Therapeutics Enters Material Definitive Agreement
Ticker: PTCT · Form: 8-K · Filed: Nov 27, 2024 · CIK: 1070081
Sentiment: neutral
Topics: material-definitive-agreement, regulation-fd
Related Tickers: PTCT
TL;DR
PTC THERAPEUTICS (PTCT) signed a big deal on Nov 26. Details TBD.
AI Summary
On November 26, 2024, PTC Therapeutics, Inc. entered into a material definitive agreement. The filing indicates this is a Regulation FD Disclosure and includes Financial Statements and Exhibits. Specific details of the agreement, including parties involved and financial terms, are not provided in this excerpt.
Why It Matters
This filing signals a significant new contract or partnership for PTC Therapeutics, which could impact its future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in this excerpt about the material definitive agreement introduces uncertainty regarding its potential impact.
Key Players & Entities
- PTC Therapeutics, Inc. (company) — Filer of the 8-K report
- November 26, 2024 (date) — Date of the earliest event reported
FAQ
What type of material definitive agreement did PTC Therapeutics, Inc. enter into?
The filing states that PTC Therapeutics, Inc. entered into a material definitive agreement on November 26, 2024, but does not specify the nature of the agreement.
Who are the other parties involved in this material definitive agreement?
The provided excerpt does not disclose the names of the other parties involved in the material definitive agreement.
Are there any financial terms or dollar amounts associated with this agreement mentioned in the filing?
No specific financial terms or dollar amounts related to the material definitive agreement are detailed in this excerpt.
What is the significance of a 'Regulation FD Disclosure' in this context?
A Regulation FD Disclosure indicates that the information being released is intended to be broadly disseminated to the public, preventing selective disclosure of material non-public information.
When was this 8-K filing submitted?
This 8-K filing was submitted on November 27, 2024.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-11-27 07:08:56
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
- $150.0 m — r ("PRV") for a purchase price equal to $150.0 million, payable in cash, upon the closin
Filing Documents
- tmb-20241126x8k.htm (8-K) — 45KB
- tmb-20241126xex99d1.htm (EX-99.1) — 15KB
- tmb-20241126xex99d1001.jpg (GRAPHIC) — 5KB
- 0001070081-24-000026.txt ( ) — 194KB
- tmb-20241126.xsd (EX-101.SCH) — 4KB
- tmb-20241126_def.xml (EX-101.DEF) — 3KB
- tmb-20241126_lab.xml (EX-101.LAB) — 16KB
- tmb-20241126_pre.xml (EX-101.PRE) — 9KB
- tmb-20241126x8k_htm.xml (XML) — 5KB
01. Entry Into a Material Definitive Agreement
Item 1.01. Entry Into a Material Definitive Agreement. On November 26, 2024, PTC Therapeutics, Inc. (the "Company") entered into an asset purchase agreement (the "PRV Transfer Agreement") with an affiliate of a large pharmaceutical company (the "Buyer"), pursuant to which the Company agreed to sell to the Buyer a Rare Pediatric Disease Priority Review Voucher ("PRV") for a purchase price equal to $150.0 million, payable in cash, upon the closing of the sale. The Company was awarded the PRV on November 13, 2024, under a U.S. Food and Drug Administration ("FDA") program intended to encourage the development of certain rare pediatric disease product applications, when its gene therapy for the treatment of aromatic l-amino acid decarboxylase deficiency was approved by the FDA. The sale of the PRV as contemplated by the PRV Transfer Agreement remains subject to customary closing conditions, including the expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The PRV Transfer Agreement contains customary representations, warranties, covenants and indemnification provisions subject to certain limitations. The foregoing description of the PRV Transfer Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the PRV Transfer Agreement, which the Company intends to file as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2024.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 27, 2024, the Company issued a press release announcing that it had entered into the PRV Transfer Agreement, furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report"). The information in this Item 7.01 of this Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Exchange Act"), except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 27, 2024 issued by PTC Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: November 27, 2024 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer